Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541413 | 0.99 | CHRM3 (0.75) | CHRM3 | |
| SCHEMBL694382 | 0.97 | CHRM3 (0.75) | CHRM3 | |
| SCHEMBL380736 | 0.92 | CHRM3 (0.75) | CHRM3 | |
| SCHEMBL694285 | 0.92 | CHRM3 (0.66) | CHRM3 | |
| SCHEMBL18239943 | 0.92 | CHRM3 (0.68) | CHRM3 | |
| Hydrochloric Acid SCHEMBL381304 | 0.92 | CHRM3 (0.74) | CHRM3 | |
| SCHEMBL693841 | 0.91 | CHRM3 (0.67) | CHRM3 | |
| SCHEMBL693467 | 0.91 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL693450 | 0.90 | CHRM3 (0.65) | CHRM3 | |
| SCHEMBL740042 | 0.89 | CHRM3 (0.75) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226082-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226082-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2A | CHRM3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.